The Power of Long-Term Investing Long-term investing is the cornerstone of wealth creation, prioritizing steady growth over fleeting market spikes. Before buying stocks, investors should go into it with the idea of…
Investors usually focus on stocks that already have stellar dividend yields, but your portfolio could also benefit from dividend growers. There are companies with solid fundamentals with a history of growing their…
There’s a well-known saying in the investing world, which advises investors to “sell in May and go away.” Historically, that has been solid advice, based on the typical seasonality of markets and…
Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, marking a 111% increase year-over-year. The company achieved a net income of $49.5 million,…
Joel South Live Updates HIMS forward guidance is exciting 5:02pm ETJoel South HOLY MOLY $HIMS JUST GUIDED TO $6.5B IN 2030 SALES WITH 20% EBITDA MARGINS 😳 pic.twitter.com/9w2fDU8rlQ — Shay Boloor (@StockSavvyShay) May 5,…
Joel South Live Updates S&P 500 Extends Its Winning Streak4:18pm ETThe S&P 500 closed up 0.6% for Tuesday, extending its winning streak to six straight days. Trade Talks Keep S&P 500 Moving Higher1:51pm ET“Ask,…
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn’t guarantee it would be able to continue selling its knockoff…
Live Updates S&P's Losing Streak, Mag 7 Correction3:29pm ETGerelyn TerzoThe markets remain under pressure as of mid-afternoon, with the exception of the Dow Jones Industrial Average, which is managing slight gains, thanks…
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO | NVO Price Prediction) was over. It said the Danish pharmaceutical had sufficient supply…
Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. About This Article Just this morning, the US FDA said Novo…
Live Updates Quantum Leap3:39pm ETGerelyn TerzoStocks have managed to find their way into positive territory as of late afternoon. The Fed is looking for further inflation progress before moving rates, according to…
Stock markets got a bit of a shock on Friday after a University of Michigan survey showed consumers are anticipating inflation to rise in 2025, potentially depressing consumer spending and dissuading the…
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli Lilly (NYSE:LLY | LLY Price Prediction) has become the industry leader in a…
Live Updates Nasdaq Composite Off Its Daily Highs2:10pm ETEric BleekerThe Nasdaq Composite has fallen from its highs today but is still up about 1% as of 2:10 p.m. ET. Information Technology stocks…
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs…
